Geddes, JR, Goodwin, GM, Rendell, J, Azorin, JM, Cipriani, A, Ostacher, MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet
2010; 375: 385–95.
Rybakowski, JK, Chlopocka-Wozniak, M, Suwalska, A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord
2001; 3: 63–7.
Garnham, J, Munro, A, Slaney, C, Macdougall, M, Passmore, M, Duffy, A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord
2007; 104: 185–90.
Kleindienst, N, Engel, RR, Greil, W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med
2005; 35: 1685–94.
Kleindienst, N, Engel, R, Greil, W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord
2005; 7: 404–17.
Berghofer, A, Alda, M, Adli, M, Baethge, C, Bauer, M, Bschor, T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry
2008; 69: 1860–8.
Rybakowski, JK. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs
2013; 27: 165–73.
Perlis, RH, Smoller, JW, Ferreira, MA, McQuillin, A, Bass, N, Lawrence, J, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry
2009; 166: 718–25.
Chen, CH, Lee, CS, Lee, MT, Ouyang, WC, Chen, CC, Chong, MY, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med
2014; 370: 119–28.
DiMatteo, MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care
2004; 42: 200–9.
Haynes, RB, McDonald, HP, Garg, AX. Helping patients follow prescribed treatment: clinical applications. JAMA
2002; 288: 2880–3.
Osterberg, L, Blaschke, T. Adherence to medication. N Eng J Med
2005; 353: 487–97.
Julius, RJ, Novitsky, MA Jr., Dubin, WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract
2009; 15: 34–44.
Colom, F, Vieta, E, Martinez-Aran, A, Reinares, M, Benabarre, A, Gasto, C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry
2000; 61: 549–55.
Murru, A, Pacchiarotti, I, Amann, BL, Nivoli, AM, Vieta, E, Colom, F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord
2013; 151: 1003–8.
Connelly, CE, Davenport, YB, Nurnberger, JI Jr. Adherence to treatment regimen in a lithium carbonate clinic. Arch Gen Psychiatry
1982; 39: 585–8.
Malhotra, AK, Zhang, JP, Lencz, T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry
2012; 17: 760–9.
Lee, MT, Chen, CH, Lee, CS, Chen, CC, Chong, MY, Ouyang, WC, et al. Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol Psychiatry
2011; 16: 548–56.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. APA, 1994.
Cheng, ATA, Tien, AY, Chang, CJ, Brugha, TS, Cooper, JE, Lee, CS, et al. Cross-cultural implementation of a Chinese version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) in Taiwan. Br J Psychiatry
2001; 178: 567–72.
Yang, YY. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand
1985; 71: 171–5.
Kane, JM, Leucht, S, Carpenter, D, Docherty, JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry
2003; 64 (suppl 12): 5–19.
Hou, L, Heilbronner, U, Rietschel, M, Kato, T, Kuo, PH, McMahon, FJ, et al. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med
2014; 370: 1857–9.
Ikeda, M, Kondo, K, Iwata, N. Variant GADL1 and response to lithium in bipolar I disorder. N Eng J Med
2014; 370: 1856–7.
Kotambail, A, Mathur, A, Bhat, SM, Rai, PS, Sharma, PS, Satyamoorthy, K. GADL1 gene polymorphisms and lithium response in bipolar I disorder: lack of association from an Indian population. Psychiatr Genet
2015; 25: 39–40.
Cruceanu, C, Alda, M, Dion, PA, Turecki, G, Rouleau, GA. No evidence for GADL1 variation as a bipolar disorder susceptibility factor in a Caucasian lithium-responsive cohort. Am J Psychiatry
2015; 172: 94–5.
Gonzalez-Pinto, A, Mosquera, F, Alonso, M, López, P, Ramírez, F, Vieta, E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord
2006; 8: 618–24.